Company
858 Therapeutics
8five8 Therapeutics - Developing a new class of targeted therapy to improve the lives of cancer patients
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for patients with advanced solid tumors.
Loading relationship preview